



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

| | | |
|--------------------------------|---|---------------------------------|
| Summary for ARTG Entry: | 310442 | NUTRA-LIFE BILBERRY 10,000 PLUS |
| ARTG entry for | Medicine Listed | |
| Sponsor | Vitaco Health Australia Pty Ltd | |
| Postal Address | PO Box 399, NORTH RYDE BC, NSW, 1670 Australia | |
| ARTG Start Date | 17/10/2018 | |
| Product Category | Medicine | |
| Status | Active | |
| Approval Area | Listed Medicines | |

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . NUTRA-LIFE BILBERRY 10,000 PLUS

| Product Type | Effective Date |
|-------------------------|----------------|
| Single Medicine Product | 17/10/2018 |

Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Helps reduce/decrease free radical damage to body cells
- Maintain/support healthy eye function
- Maintain/support eye health
- Helps maintain/support eye macula health
- Helps maintain/support eye retina health
- Maintain/support healthy eyesight/vision
- Maintain/support general health and wellbeing
- Maintain/support red blood cell health
- Maintain/support cardiovascular system health
- Maintain/support healthy cardiovascular system function
- Maintain/support blood capillary health
- Maintain/support blood vessel health
- Maintain/support immune system health
- Maintain/support healthy immune system function
- Helps prevent dietary (state vitamin/mineral/nutrient) deficiency

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to serious cardiovascular conditions.



Australian Government
Department of Health
 Therapeutic Goods Administration

Product presentation must not imply or refer to serious immunological diseases.

Product presentation must not imply or refer to vision correction, faults or serious eye disease e.g. macular degeneration.

Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Visual Identification

Active Ingredients

| | |
|--|-----------------|
| ascorbic acid | 262.5 mg |
| betacarotene | 3 mg |
| chromic chloride hexahydrate | 256.6 microgram |
| Equivalent: chromium | 50 microgram |
| Citrus bioflavonoids extract | 50 mg |
| d-alpha-tocopheryl acid succinate | 62.6 mg |
| glutamine | 25 mg |
| lutein | 6 mg |
| nicotinamide | 10 mg |
| riboflavin | 25 mg |
| rutoside | 50 mg |
| taurine | 50 mg |
| Vaccinium myrtillus fruit Extract dry concentrate standardised | 100 mg |
| Equivalent: Vaccinium myrtillus (Fresh) | 10 g |
| Vitis vinifera seed Extract dry concentrate | 25 mg |
| Equivalent: Vitis vinifera (Dry) | 3 g |
| zinc amino acid chelate | 75 mg |
| Equivalent: zinc | 15 mg |

Other Ingredients (Excipients)

- calcium hydrogen phosphate
- crospovidone
- dl-alpha-tocopherol
- hypromellose
- iron oxide black
- iron oxide red
- iron oxide yellow
- liquid glucose
- macrogol 3350

Public Summary



Australian Government

Department of Health
Therapeutic Goods Administration

magnesium stearate
maize starch
microcrystalline cellulose
polyvinyl alcohol
povidone
purified talc
purified water
silicon dioxide
sodium ascorbate
starch sodium octenyl succinate
sucrose

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary